The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated•Originally published 1 May 2026•Updated 3 May 2026•

1 min read

Mizuho and UBS Adjust Price Targets for ResMed, Veralto, and L3Harris

Key Facts

1Mizuho Securities lowered its price target for RMD to $235 from $255 while maintaining an Outperform rating.

2UBS increased its price target for VLTO to $101 from $99 while keeping a Neutral rating.

3UBS adjusted its price target for LHX to $330 from $362 despite the company raising its 2026 profit forecast.

Major financial institutions have updated their outlooks for key industrial and healthcare firms, with Mizuho lowering its ResMed (RMD) price target to $235 despite the company beating earnings expectations with a $2.86 EPS and 11% revenue growth. RMD shares fell 7.7% this week as markets reacted to concerns over the impact of GLP1 drugs and a transition in the CFO role. Meanwhile, UBS adjusted its target for Veralto (VLTO) upward to $101 while maintaining a Neutral stance. For L3Harris (LHX), UBS reduced the target price to $330 even as the company raised its 2026 profit guidance amid high demand. These revisions highlight a complex landscape where strong quarterly results are being weighed against shifting sector dynamics. Investors remain focused on how these firms navigate executive changes and evolving competitive pressures.

about 1 month ago

Version History

Version 1about 1 month ago

What changed: Added ResMed's Q3 earnings beat (EPS and revenue growth) and detailed the 7.7% weekly stock drop linked to GLP1 concerns and the CFO transition.